Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference Format: Management will participate in a fireside chat and investor meetings Date: Wednesday, March 4 at 10:30 a.m. ET Leerink Global Healthcare Conference Format: Management will participate in a fireside chat and investor

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the "Inducement Grant") on February 2, 2026 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Ru

Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025 Completion of dosing in Embolden expected in second quarter of 2026 Plan to present interim data on pediatric and adolescent/adult cohorts from Phase 1/2 trial in mid-2026 Early commercial-readiness activities underway Neurogene to present at J.P. Morgan Healthcare Conference on January 14 at 7:30 a.m. PT Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on recent achievements for NGN-401 gene therapy for the treatment of Rett syndrome and plans for mul

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference. Format: Management will present a company overview and participate in investor meetings Date: Wednesday, January 14 at 7:30 a.m. PT A webcast of the presentation will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene The mission of Neurogene is to treat devastating neurological diseases t

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 4,860 shares of the Company's common stock to two new employees (the "Inducement Grants") on December 2, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance w

Reported positive interim data from NGN-401 Phase 1/2 gene therapy trial for Rett syndrome demonstrating multidomain, durable gains, with 35 total developmental milestones/skills acquired across eight participants First participant dosed in Embolden™ registrational trial of NGN-401 for Rett syndrome, with complete enrollment expected in three to six months Strong cash position provides runway through first quarter of 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2025 financial results and highlighted recent corporate updates. "

Multidomain, durable gains with continued skill acquisition over time All 8 participants showed functional gains across spectrum of disease severity 35 total developmental milestones/skills acquired across 8 participants NGN-401 at the registrational dose continues to be generally well-tolerated, with no evidence of HLH Neurogene management to discuss results during Stifel 2025 Healthcare Conference webcast today at 4:40 p.m. ET Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive, updated interim clinical data in the pediatric cohort (ages 4

Single trial to support future BLA submission for NGN-401 in patients ages ≥ 3 years Rapid trial execution underway with 12 of 13 clinical sites initiated Expect to complete trial enrollment in three to six months Neurogene management to present Phase 1/2 interim data update at Stifel Healthcare Conference on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first participant was dosed in the Embolden™ registrational clinical trial of NGN-401, a gene therapy in development for the treatment of Rett syndrome. NGN-401 has the potential

Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 1,185 shares of the Company's common stock to one new employee (the "Inducement Grant") on November 4, 2025 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasd

Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV administration is superior to IT-L in reaching key brain regions underlying Rett syndrome As previously reported, the first four participants in the NGN-401 Phase 1/2 trial gained 23 developmental milestones/skills, representing multi-domain improvement that requires transduction of key brain regions and nervous system The preclinical data also provide evidence-based confirmation that ICV and IT-L administration result in comparable peripheral organ transduction, showing n